These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12953139)

  • 41. Review of placebo-controlled trials with bupropion.
    Zung WW
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):104-14. PubMed ID: 6406436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antidepressants on trial: how valid is the evidence?
    Parker G
    Br J Psychiatry; 2009 Jan; 194(1):1-3. PubMed ID: 19118316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of study design on the results of continuation studies of antidepressants.
    Zimmerman M; Posternak MA; Ruggero CJ
    J Clin Psychopharmacol; 2007 Apr; 27(2):177-81. PubMed ID: 17414242
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A double-blind, placebo-controlled study of paroxetine in depressed outpatients.
    Kiev A
    J Clin Psychiatry; 1992 Feb; 53 Suppl():27-9. PubMed ID: 1531818
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluvoxamine: a review of the controlled trials in depression.
    Ware MR
    J Clin Psychiatry; 1997; 58 Suppl 5():15-23. PubMed ID: 9184623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis.
    Posternak MA; Zimmerman M
    Br J Psychiatry; 2007 Apr; 190():287-92. PubMed ID: 17401033
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Novel Study Design to Systematically Explore the Impact of Trial Methodology on Psychopharmacological Treatment Outcome in Patients with Depression.
    Severus E; Sauer C; Bauer M; Ostacher M; Anghelescu IG
    Pharmacopsychiatry; 2019 Jul; 52(4):170-174. PubMed ID: 29975972
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression.
    March JS; Kobak KA; Jefferson JW; Mazza J; Greist JH
    J Clin Psychiatry; 1990 May; 51(5):200-2. PubMed ID: 2110560
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Burdens and benefits of placebos in antidepressant clinical trials: a decision and cost-effectiveness analysis.
    Kim SY; Holloway RG
    Am J Psychiatry; 2003 Jul; 160(7):1272-6. PubMed ID: 12832241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Considering the case for an antidepressant drug trial involving temporary deception: a qualitative enquiry of potential participants.
    Dowrick CF; Hughes JG; Hiscock JJ; Wigglesworth M; Walley TJ
    BMC Health Serv Res; 2007 Apr; 7():64. PubMed ID: 17470280
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials.
    Khan A; Khan SR; Shankles EB; Polissar NL
    Int Clin Psychopharmacol; 2002 Nov; 17(6):281-5. PubMed ID: 12409681
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A meta-analysis of fluoxetine outcome in the treatment of depression.
    Greenberg RP; Bornstein RF; Zborowski MJ; Fisher S; Greenberg MD
    J Nerv Ment Dis; 1994 Oct; 182(10):547-51. PubMed ID: 7931201
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nefazodone: aspects of efficacy.
    Rickels K; Robinson DS; Schweizer E; Marcus RN; Roberts DL
    J Clin Psychiatry; 1995; 56 Suppl 6():43-6. PubMed ID: 7649973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy.
    Bschor T; Baethge C
    Acta Psychiatr Scand; 2010 Mar; 121(3):174-9. PubMed ID: 19703121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pills or placebos?
    Trussell J
    Science; 1999 May; 284(5416):913. PubMed ID: 10357672
    [No Abstract]   [Full Text] [Related]  

  • 58. Differing antidepressant maintenance methodologies.
    Safer DJ
    Contemp Clin Trials; 2017 Oct; 61():87-95. PubMed ID: 28739537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
    Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI
    J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.
    Dominguez RA; Goldstein BJ; Jacobson AF; Steinbook RM
    J Clin Psychiatry; 1985 Mar; 46(3):84-7. PubMed ID: 3918993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.